Course Overview & Short Introduction

Valeria Vitelli

Oslo Centre for Biostatistics and Epidemiology
Department of Biostatistics, UiO
valeria.vitelli@medisin.uio.no

MED3007

Statistical Principles in Genomics: an Introduction with Rstudio 13.01.2025

- Course Overview
 - Course summary & schedule
 - Take-home Exam

- Short Introduction to the Topic
 - Common statistical tasks with large-scale biological data
 - Group Work

Course Content

Motivations

- molecular (genomic) data increasingly important in medical research
 & clinical practice
- ullet such data are *very high-dimensional* o challenges

Aims

- general: learn the challenges & solutions when analysing genomic data, both in theory and practice
- theory: focus on three main tasks; screening, visualisation, clustering
- practice: introduction to RStudio, many examples

Course Structure

General structure

- afternoon:
 - lecture on a topic + Q & A session
 - some free time for reflection / group work
- morning after: practical lab session on the same topic

	Monday	Tuesday	Wednesday	Thursday	Friday
9:00 - 9:45	Intro Course	Intro Lab 1	Lab 2	Lab 3	
10:00 - 11:30	Intro RStudio	Lab 1	Exercises	Exercises	
11:30 - 12:30	lunch	lunch	lunch	lunch	Exam
12:30 - 13:30	Lecture 1	Lecture 2	Lecture 3	Exam Sim	
13:30 - 15:30	Group Work	Group Work	Group Work	Wrap-up	

Special Sessions

Thursday is quite interactive. Used to fix concepts from the course, to ask questions, and to see a take-home exam simulation.

Practical Info

Website

More interactive website we will use for teaching materials: https://ocbe-uio.github.io/course_med3007/

Canvas

- Course webpage on Canvas: https://www.uio.no/studier/emner/medisin/med/MED3007
- https://uio.instructure.com and Mobile App Canvas Student (for iOS and Android)
- All course material (lecture notes, computer labs, data sets, reading material) will be ALSO made available via Canvas
- If you have problems logging in, send me email asap!

Info on the course Take-home Exam

Idea

- The purpose of the exam is to replicate one of the analyses we will see in class
- Any proposal will be accepted. The focus is not on right/wrong answers, but on showing independence in managing high-dimensional data analysis: choosing a method for a given purpose

Details

- Starting point is a data set, which will be provided via Inspera on Thursday at 15:00
- You have time until Monday same time
- You can provide your analysis as a .pdf or .doc file, or as a .R (or .Rmd) file. Important is to report what you think is relevant for me to understand what you did and why you did what you did

- Course Overview
 - Course summary & schedule
 - Take-home Exam

- Short Introduction to the Topic
 - Common statistical tasks with large-scale biological data
 - Group Work

Sickle cell anemia, a molecular disease (Pauling et al, 1949)

November 25, 1949, Vol. 110


SCIENCE

543

Sickle Cell Anemia, a Molecular Disease¹

Linus Pauling, Harvey A. Itano,² S. J. Singer,² and Ibert C. Wells³

Gates and Crellin Laboratories of Chemistry, California Institute of Technology, Pasadena, California





Sickle cell anemia, a molecular disease (Pauling et al, 1949)

- Pauling et al. showed that hemoglobin from patients suffering from sickle cell anemia had a different electrical charge than that from healthy individuals.
- This report had a powerful impact on both the biomedical community and the general public for two reasons:
 - It showed that the cause of a disease could be traced to an alteration in the molecular structure of a protein.
 - As this disease was known to be inherited, the paper argued that genes determine the structure of proteins.

Biomarkers / molecular markers

Biomarker

We refer to a biomarker as a biological quantitative measure associated with a clinical outcome. It may be a single trait, or a grouping (signature) of traits that separates different populations with respect to an outcome of interest." (Sargent *et al.*, 2005)^a.

Examples: classic laboratory parameters (blood pressure, cholesterol level, blood glucose) and molecular markers.

Molecular marker

A molecular marker is a biomarker that can be detected using genomics and/or proteomics technologies.

Examples: gene mutations, gene expression, protein expression, methylation patterns.

^aSargent, D. J., Conley, B. A., Allegra, C., & Collette, L. (2005). Clinical trial designs for predictive marker validation in cancer treatment trials. *Journal of Clinical Oncology*, 23(9), 2020-2027.

Molecular diagnostics

It means to identify molecular markers in the genome by applying molecular biology to medical testing. The technique is used to diagnose and monitor disease, detect risk, and decide which therapies will work best for individuals.

Examples:

- Prenatal tests for chromosomal abnormalities (e.g. Trisomy 21)
- Infectious diseases: test for infectious diseases such as chlamydia, influenza virus and tuberculosis; or for specific strains such as the H1N1 virus (pathogenomics).
- Cancer screening: for example testing for mutations in BRCA1 or BRCA2 for familial form of breast cancer (about 5% of all breast & ovarian cancers) → "Angelina Jolie" effect

Statistical Principles in Genomics

- The main difference to "classical statistics" is the **high-dimensionality of the data**: in genomic data we have tens of thousands or millions of input variables/ features.
- Most of those features will not be of interest in the specific context of the experiment. \rightarrow The main task is the **identification of important** features (genes, SNP's, etc).
- We have to deal with the curse of dimensionality.

References:

- James et al. (2013) An Introduction to Statistical Learning with Applications in R, https://www.statlearning.com/, Chapters: 1, 2, 12, 13
- Holmes, Huber (2019). Modern Statistics for Modern Biology, http://web.stanford.edu/class/bios221/book/ Chapters: 3, 5, 6, 7

Statistical Principles in Genomics

- Screening and multiple testing (to determine lists of differentially expressed genes)
- Exploratory analysis and unsupervised learning
 - Exploratory analysis: Dimension reduction and visualisation (ex. principal components analysis)
 - Unsupervised learning: Clustering and heatmaps (ex. to find subgroups of similarly regulated genes)

	Monday	Tuesday	Wednesday	Thursday	Friday
9:00 - 9:45	Intro Course	Intro Lab 1	Lab 2	Lab 3	
10:00 - 11:30	Intro RStudio	Lab 1	Exercises	Exercises	
11:30 - 12:30	lunch	lunch	lunch	lunch	Exam
12:30 - 13:30	Lecture 1	Lecture 2	Lecture 3	Exam Sim	
13:30 - 15:30	Group Work	Group Work	Group Work	Wrap-up	

Info on the course Group Work

Idea

- The purpose of the group work is to find practical examples of the analyses we will see in class
- Aim: Get the discussion going. The focus is not on right/wrong answers, but on discussing issues seen in class in a practical setting

Details

- Starting point: **two papers**, paper 1 and paper 2 (see next slides)
- Paper 1 is related to Lecture 1 and 2; Paper 2 to Lecture 3
- Group Work: what are you supposed to do? Read the paper, and try to answer in groups to the following questions
 - Which was the main research question addressed in the paper?
 - Where do results of methods seen in class are reported in the paper? (which figures/tables)

Paper 1 (focus for Lectures 1 & 2)

Cappelletti et al. Clinical Proteomics (2022) 19:23 https://doi.org/10.1186/s12014-022-09361-1

Clinical Proteomics

RESEARCH

Open Access

Quantitative proteomics reveals protein dysregulation during T cell activation in multiple sclerosis patients compared to healthy controls

Chiara Cappelletti¹, Anna Eriksson³, Ina Skaara Brorson^{3,4}, Ingvild S. Leikfoss^{3,4}, Oda Kråbøl², Einar August Høgestøl^{3,4,5}, Valeria Vitelli⁶, Olav Mjaavatten⁷, Hanne F. Harbo^{3,4}, Frode Berven⁷, Steffan D. Bos⁴ and Tone Berge^{1,2*} •

Paper 2 (focus for Lecture 3)

Published online 24 March 2022

NAR Cancer, 2022, Vol. 4, No. 1 1 https://doi.org/10.1093/narcan/zcac008

Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer

Jørgen Ankill ^{©1,2}, Miriam Ragle Aure ^{©3}, Sunniva Bjørklund ^{©3}, Severin Langberg ^{©4}, Oslo Breast Cancer Consortium (OSBREAC), Vessela N. Kristensen ^{©3}, Valeria Vitelli ^{©5}, Xavier Tekpli ^{©3} and Thomas Fleischer ^{©1,*}

¹Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway, ²Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway, ³Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway, ⁴Cancer Registry of Norway, Oslo, Norway and ⁵Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Faculty of Medicine, University of Oslo, Oslo, Norway